Demant ASWBO:DEMA -0.89%96 ROE % is 8.89% as of Dec. 2025, which is 61% below its 10-year median of 23.03. GuruFocus rates WBO:DEMA with a GF Score™ of 96/100 and a GF Value™ of €41.71. The stock has 5 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Demant AS ranks better than 87.36% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Demant AS's annualized net income for the quarter that ended in Dec. 2025 was €115 Mil. Demant AS's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €1,289 Mil. Therefore, Demant AS's annualized ROE % for the quarter that ended in Dec. 2025 was 8.89%.
The historical rank and industry rank for Demant AS's ROE % or its related term are showing as below:
WBO:DEMA'
s ROE % Range Over the Past 10 Years
Min: 14.11 Med: 23.03 Max: 30.97
Current: 16.09
During the past 13 years, Demant AS's highest ROE % was 30.97%. The lowest was 14.11%. And the median was 23.03%.
WBO:DEMA's ROE % is ranked better than 87.36% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs WBO:DEMA: 16.09
Demant AS (WBO:DEMA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Demant AS ROE % Related Terms
Demant AS ROE % Historical Data
* Premium members only.
The historical data trend for Demant AS's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Demant AS's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Demant AS ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Demant AS's ROE % distribution charts can be found below:
* The bar in red indicates where Demant AS's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Demant AS (WBO:DEMA) has a ROE % of 8.89% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Demant AS and its competitors. This is 61% below median its historical median of 23.03. Over the past decade, Demant AS's ROE % has ranged from 14.11 to 30.97. According to the industry distribution chart, Demant AS ranks #101 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 12.6%.
Is Demant AS's ROE % too high?
Demant AS's current ROE % of 8.89% is 61% below median its 10-year median of 23.03. Over the past 10 years, this metric has ranged from a low of 14.11 to a high of 30.97. The Medical Devices & Instruments industry median ROE % is 2.42. Demant AS's value of 8.89% is 267.4% above this industry median. Based on the distribution chart, Demant AS ranks #101 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Demant AS has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Demant AS's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Demant AS ranks #101 out of 799 companies for ROE %. This places Demant AS in the top 13% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Demant AS's value of 8.89% is 267.4% above this benchmark. Historically, Demant AS's own ROE % has ranged from 14.11 to 30.97 over the past decade. While the company's 10-year median is 23.03 vs. the industry median of 2.42, Demant AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Demant AS's current ROE % of 8.89% is 267.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Demant AS and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Demant AS's current ROE % is 8.89%, which is 61% below median its own 10-year median of 23.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Demant AS stock overvalued right now?
Demant AS (WBO:DEMA) has a current ROE % of 8.89%. The stock's GF Value™ is €41.71, compared to a current price of €35.72 — trading 14.4% below its estimated fair value. The current ROE % is 8.89%, which is 61% below median its 10-year median of 23.03 and 267.4% above the Medical Devices & Instruments industry median of 2.42. Demant AS's overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Demant AS (WBO:DEMA), the current ROE % is 8.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Demant AS (WBO:DEMA) Overvalued in 2026?
Based on GuruFocus' analysis, Demant AS stock appears to be undervalued.
The current stock price of €35.72 is trading 14.4% below its estimated GF Value™ of €41.71.
Key valuation signals for WBO:DEMA:
ROE %: 8.89% (61% below median its 10-year median of 23.03)
GF Value™: €41.71 vs. price of €35.72 (14.4% below fair value)
Industry Position: 267.4% above the Medical Devices & Instruments median (#101 of 799)
No single metric tells the full story. See the WBO:DEMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Demant is a Denmark-based manufacturer and distributor of hearing solutions, such as hearing aid devices and diagnostic equipment. More than 80% of the company's sales come from North America and Europe.
96GF Score
Get the complete analysis for WBO:DEMA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DEMA has been successfully added to your 
